Shattuck falls as quarterly net loss widens
STTK•Cash position and outlook
The company said it had $208.3 million in cash and cash equivalents and investments as of June 30, which it expects will fund operations into 2029.
Shattuck is specializing in the development of potential treatments for inflammatory and immune-mediated diseases.
Up to the last close, the stock was up 95.6% year to date.
Shares fall premarket after wider quarterly loss
Shares of drug developer Shattuck Labs fell 1.8% to $7.01 premarket after the company reported a wider quarterly net loss.
The company reported second-quarter net loss of $15.2 million compared with a net loss of $12.5 million a year ago. Shattuck's second-quarter research and development expenses rose 34% to $11.7 million.
Analysts, on average, expected R&D expense of $10.9 million, according to LSEG data.
